絞り込み

16287

広告

Potential role of immunotherapy in advanced non-small-cell lung cancer.

著者 de Mello RA , Veloso AF , Esrom Catarina P , Nadine S , Antoniou G
Onco Targets Ther.2017 ; 10():21-30.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)
  • このエントリーをはてなブックマークに追加

Miscellaneous

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework.
PMID: 28031719 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード